Immunotherapies Targeting Amyloid and Tau Protein in Alzheimer’s Disease: Should We Move Away from Diseases and Focus on Biological Targets? A Systematic Review and Expert Opinion
Tóm tắt
Alzheimer’s disease (AD) is the most common cause of dementia worldwide, making it a major public health issue. Anti-amyloid and anti-tau antibodies are the most advanced therapeutic approach at present. Three drugs (lecanemab, donanemab and aducanumab) are on track to be marketed in the coming months. In this systematic review, we review all Phase 2 and Phase 3 clinical trials conducted in this indication and the particularities of the molecules tested. The PubMed and ClinicalTrials.gov databases were searched through February 2023 for Phase 2 and 3 clinical trials involving passive anti-amyloid or anti-tau immunotherapies with published results. This review has been compiled in compliance with the PRISMA checklists. Of the 165 studies found and after eliminating duplicates, 40 studies had their results published on PubMed and/or ClinicalTrials.gov. Eight anti-amyloid molecules and four anti-tau molecules were the subject of Phase 2 studies, seven anti-amyloids were the subject of Phase 3 trials, and two molecules were granted early marketing approval by the US Food and Drug Administration (FDA). The results were compiled in summary tables showing the primary endpoints used, results, age of the study population and specific adverse events for these molecules. Passive immunotherapy in AD is largely dominated by anti-amyloid antibodies, which are more numerous and more advanced in the pipeline. Lecanemab, donanemab and aducanumab are distinguished by their relative efficacy in terms of cognitive and functional evaluation but also by a decrease in amyloid and tau proteins in the brain. These three molecules have in common that they bind to N-terminal ends of amyloid fibrils and plaques. The findings of their studies raise the question of which criteria to apply when choosing which patient will receive them when marketed, such as the apoliprotein E gene’s fourth allele (APOE4) genetic status of patients. The large number of negative studies may also raise the question of the criteria for defining the disease and the possible interest in redefining it on biological grounds to offer a more personalized medicine to patients suffering from neurodegenerative diseases.
Tài liệu tham khảo
Dementia [Internet]. https://www.who.int/news-room/fact-sheets/detail/dementia. Accessed 1 Dec 2022.
Dumurgier J, Sabia S. Epidemiology of Alzheimer’s disease: latest trends. Rev Prat. 2020;70:149–51.
Alzheimer’s disease facts and figures. Alzheimers Dement. 2022;18:700–89.
Dubois B, et al. Research criteria for the diagnosis of Alzheimer’s disease: revising the NINCDS–ADRDA criteria. Lancet Neurol. 2007;6:734–46.
Gorno-Tempini ML, et al. Classification of primary progressive aphasia and its variants. Neurology. 2011;76:1006–14.
Thal DR, et al. Phases of Aβ-deposition in the human brain and its relevance for the development of AD. Neurology. 2002;58:1791–800.
Caselli RJ, et al. Alzheimer disease: scientific breakthroughs and translational challenges. Mayo Clin Proc. 2017;92:978–94.
Vijaya Kumar DK, et al. Amyloid-β Peptide Protects Against Microbial Infection In Mouse and Worm Models of Alzheimer’s Disease. Sci Transl Med. 2016;8:340ra72.
Hampel H, et al. The Amyloid-β Pathway in Alzheimer’s Disease. Mol Psychiatry. 2021;26:5481–503.
Morris M, et al. The many faces of tau. Neuron. 2011;70:410–26.
Milà-Alomà M, et al. Amyloid beta, tau, synaptic, neurodegeneration, and glial biomarkers in the preclinical stage of the Alzheimer’s continuum. Alzheimers Dement J Alzheimers Assoc. 2020;16:1358–71.
DeTure MA, Dickson DW. The neuropathological diagnosis of Alzheimer’s disease. Mol Neurodegener. 2019;14:32.
Levine, Kristin S et al. Virus exposure and neurodegenerative disease risk across national biobanks. Neuron 2023; 111(7):1086–1093.e2. https://doi.org/10.1016/j.neuron.2022.12.029.
Dominy SS, et al. Porphyromonas gingivalis in Alzheimer’s disease brains: Evidence for disease causation and treatment with small-molecule inhibitors. Sci Adv. 2019;5:eaau3333.
Tan C-C, et al. Efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer’s disease: a systematic review and meta-analysis. J Alzheimers Dis. 2014;41:615–31.
Amieva H, et al. Group and individual cognitive therapies in Alzheimer’s disease: the ETNA3 randomized trial. Int Psychogeriatr. 2016;28:707–17.
Sitzer DI, et al. Cognitive training in Alzheimer’s disease: a meta-analysis of the literature. Acta Psychiatr Scand. 2006;114:75–90.
Plotkin SS, Cashman NR. Passive immunotherapies targeting Aβ and tau in Alzheimer’s disease. Neurobiol Dis. 2020;144: 105010.
Lu L, et al. Anti-Aβ agents for mild to moderate Alzheimer’s disease: systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. 2020;91:1316–24.
Cummings J, et al. Alzheimer’s disease drug development pipeline: 2022. Alzheimers Dement N Y N. 2022;8: e12295.
Bouter Y, et al. Abeta targets of the biosimilar antibodies of Bapineuzumab, Crenezumab, Solanezumab in comparison to an antibody against N-truncated Abeta in sporadic Alzheimer disease cases and mouse models. Acta Neuropathol (Berl). 2015;130:713–29.
Doody RS, et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer’s disease. N Engl J Med. 2014;370:311–21.
Honig LS, et al. Trial of solanezumab for mild dementia due to Alzheimer’s disease. N Engl J Med. 2018;378:321–30.
Salloway S, et al. A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer’s disease. Nat Med. 2021;27:1187–96.
Leurent C, et al. Immunotherapy with ponezumab for probable cerebral amyloid angiopathy. Ann Clin Transl Neurol. 2019;6:795–806.
La Porte SL, et al. Structural basis of C-terminal β-amyloid peptide binding by the antibody ponezumab for the treatment of Alzheimer’s disease. J Mol Biol. 2012;421:525–36.
Landen JW, et al. Multiple-dose ponezumab for mild-to-moderate Alzheimer’s disease: Safety and efficacy. Alzheimers Dement Transl Res Clin Interv. 2017;3:339–47.
Ostrowitzki S, et al. Evaluating the safety and efficacy of crenezumab vs placebo in adults with early alzheimer disease: two phase 3 randomized placebo-controlled trials. JAMA Neurol. 2022;79:1113.
Söderberg L et al. Lecanemab, aducanumab, and gantenerumab-binding profiles to different forms of amyloid-beta might explain efficacy and side effects in clinical trials for Alzheimer’s disease. Neurother J Am Soc Exp Neurother. 2023;20(1):195–206.
The SCarlet RoAD Investigators. A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease. Alzheimers Res Ther. 2017;9:95.
Trontinemab | ALZFORUM [Internet]. https://www.alzforum.org/therapeutics/trontinemab. Accessed 9 Mar 2023.
Hoffmann-La Roche. A Phase Ib/IIa, Randomized, Double Blind, Placebo-Controlled, Multiple Ascending Dose, Parallel-Group Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7126209 Following Intravenous Infusion in Patients With Prodromal or Mild to Moderate Alzheimer’s Disease [Internet]. clinicaltrials.gov; 2023 Feb. Report No.: NCT04639050. Available from: https://clinicaltrials.gov/ct2/show/NCT04639050
van Dyck CH et al. Lecanemab in early Alzheimer’s disease. N Engl J Med 2023; 388(1):9–21. https://doi.org/10.1056/NEJMoa2212948.
Commissioner O of the. FDA Grants Accelerated Approval for Alzheimer’s Drug [Internet]. FDA. FDA; 2021. https://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-alzheimers-drug. Accessed 22 Nov 2022.
Budd Haeberlein S, et al. Two randomized phase 3 studies of aducanumab in early Alzheimer’s disease. J Prev Alzheimers Dis Internet. 2022. https://doi.org/10.14283/jpad.2022.30.
Maloney and Pallone Release Staff Report on Review, Approval, and Pricing of Biogen’s Alzheimer’s Drug Aduhelm [Internet]. Democr. Energy Commer. Comm. 2022. https://democrats-energycommerce.house.gov/newsroom/press-releases/maloney-and-pallone-release-staff-report-on-review-approval-and-pricing-of. Accessed 3 Mar 2023.
Salloway S, et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer’s disease. N Engl J Med. 2014;370:322–33.
Gueorguieva I, et al. Donanemab Population Pharmacokinetics, Amyloid Plaque Reduction, and Safety in Participants with Alzheimer's disease. Clin Pharmacol Ther. 2023; 113(6):1258–67. https://doi.org/10.1002/cpt.2875.
DeMattos RB, et al. A plaque-specific antibody clears existing β-amyloid Plaques in Alzheimer’s disease mice. Neuron. 2012;76:908–20.
Mintun MA, et al. Donanemab in early Alzheimer’s disease. N Engl J Med. 2021;384:1691–704.
Lilly’s Donanemab Significantly Slowed Cognitive and Functional Decline in Phase 3 Study of Early Alzheimer’s Disease | Eli Lilly and Company [Internet]. https://investor.lilly.com/news-releases/news-release-details/lillys-donanemab-significantly-slowed-cognitive-and-functional. Accessed 13 May 2023.
Sims JR et al. Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial. JAMA [Internet]. 2023. https://jamanetwork.com/journals/jama/fullarticle/2807533. Accessed 25 July 2023.
Teng E, et al. Safety and efficacy of semorinemab in individuals with prodromal to mild alzheimer disease: a randomized clinical trial. JAMA Neurol. 2022;79:758.
Qureshi IA, et al. A randomized, single ascending dose study of intravenous BIIB092 in healthy participants. Alzheimers Dement Transl Res Clin Interv. 2018;4:746–55.
Top-line results from tango, a phase 2 study of gosuranemab in participants with mild cognitive impairment due to alzheimer’s disease and mild alzheimer’s disease | Cochrane Library [Internet]. [cited 2022 Nov 29]. https://doi.org/10.1002/central/CN-02348792/full.
Yanamandra K, et al. Anti-tau antibody reduces insoluble tau and decreases brain atrophy. Ann Clin Transl Neurol. 2015;2:278–88.
AbbVie. A Phase 2 Multiple Dose, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Subjects With Early Alzheimer’s Disease [Internet]. clinicaltrials.gov; 2022 Aug. Report No.: NCT02880956. Available from: https://clinicaltrials.gov/ct2/show/NCT02880956
AbbVie. An Extension Study of ABBV-8E12 in Early Alzheimer’s Disease [Internet]. clinicaltrials.gov; 2022 Aug. Report No.: NCT03712787. Available from: https://clinicaltrials.gov/ct2/show/NCT03712787
Jicha GA, et al. Alz-50 and MC-1, a new monoclonal antibody raised to paired helical filaments, recognize conformational epitopes on recombinant tau. J Neurosci Res. 1997;48:128–32.
Andrews JS, et al. Disease severity and minimal clinically important differences in clinical outcome assessments for Alzheimer’s disease clinical trials. Alzheimers Dement Transl Res Clin Interv. 2019;5:354–63.
Malpas CB, et al. Alzheimer’s Disease Neuroimaging Initiative. Tau and Amyloid-β cerebrospinal fluid biomarkers have differential relationships with cognition in mild cognitive impairment. J Alzheimers Dis JAD. 2015;47:965–75.
Blanc F, et al. Cortical thickness in dementia with lewy bodies and alzheimer’s disease: a comparison of prodromal and dementia stages. PLoS ONE. 2015;10: e0127396.
Tanne JH. Lecanemab: US Veterans Health Administration will cover cost of new Alzheimer’s drug. BMJ. 2023;380: p628.
Lecanemab-irmb (LEQEMBI) Criteria for Use February 2023.
ICER Publishes Final Evidence Report and Policy Recommendations on Aducanumab for Alzheimer’s Disease [Internet]. ICER. https://icer.org/news-insights/press-releases/icer-publishes-final-evidence-report-and-policy-recommendations-on-aducanumab-for-alzheimers-disease/. Accessed 3 Mar 2023.
ICER Publishes Evidence Report on Lecanemab for Alzheimer’s Disease [Internet]. ICER. https://icer.org/news-insights/press-releases/icer-publishes-evidence-report-on-lecanemab-for-alzheimers-disease/. Accessed 19 Mar 2023.
Commissioner O of the. FDA Converts Novel Alzheimer’s Disease Treatment to Traditional Approval [Internet]. FDA. FDA; 2023. https://www.fda.gov/news-events/press-announcements/fda-converts-novel-alzheimers-disease-treatment-traditional-approval. Accessed 9 Aug 2023.
Reardon S. FDA approves Alzheimer’s drug lecanemab amid safety concerns. Nature. 2023;613:227–8.
Constantino AK. Eli Lilly expects FDA decision on Alzheimer’s treatment donanemab by the end of the year [Internet]. CNBC. 2023. https://www.cnbc.com/2023/07/17/alzheimers-eli-lilly-expects-fda-decision-on-donanemab-by-year-end.html. Accessed 9 Aug 2023.
Mead S, Fox NC. Lecanemab slows Alzheimer’s disease: hope and challenges. Lancet Neurol. 2023;22:106–8.
Wolk DA, et al. A step forward in the fight against dementia—are we there yet? JAMA Neurol. 2023;80:429–30.
Todd S, et al. Survival in dementia and predictors of mortality: a review. Int J Geriatr Psychiatry. 2013;28:1109–24.
Blanc F, et al. Long-term cognitive outcome of Alzheimer’s disease and dementia with Lewy bodies: dual disease is worse. Alzheimers Res Ther. 2017;9:47.
Panza F, et al. A critical appraisal of amyloid-β-targeting therapies for Alzheimer disease. Nat Rev Neurol. 2019;15:73–88.
Linard M, et al. Herpes simplex virus, early neuroimaging markers and incidence of Alzheimer’s disease. Transl Psychiatry. 2021;11:414.
Gilman S, et al. Clinical effects of A immunization (AN1792) in patients with AD in an interrupted trial. Neurology. 2005;64:1553–62.
TauRx Announces Results from Phase 3 Alzheimer’s Disease Study,… [Internet]. TauRx Pharm. https://taurx.com/news-insights/taurx-announces-results-from-phase-3-alzheimers-disease-study-lucidity-assuring-path-for-regulatory-submissions. Accessed 27 Mar 2023.
Novo Nordisk A/S. A Randomised Double-blind Placebo-controlled Clinical Trial Investigating the Effect and Safety of Oral Semaglutide in Subjects With Early Alzheimer´s Disease (EVOKE) [Internet]. clinicaltrials.gov; 2023 Mar. Report No.: NCT04777396. Available from: https://clinicaltrials.gov/ct2/show/NCT04777396
Novo Nordisk A/S. A Randomised Double-blind Placebo-controlled Clinical Trial Investigating the Effect and Safety of Oral Semaglutide in Subjects With Early Alzheimer´s Disease (EVOKE Plus) [Internet]. clinicaltrials.gov; 2023 Mar. Report No.: NCT04777409. Available from: https://clinicaltrials.gov/ct2/show/NCT04777409
Sarto J, et al. Evolution of clinical-pathological correlations in early-onset alzheimer’s disease over a 25-year period in an academic brain bank. J Alzheimers Dis JAD. 2022;87:1659–69.
Agrawal S, et al. The association of Lewy bodies with limbic-predominant age-related TDP-43 encephalopathy neuropathologic changes and their role in cognition and Alzheimer’s dementia in older persons. Acta Neuropathol Commun. 2021;9:156.
Robinson JL, et al. Pathological combinations in neurodegenerative disease are heterogeneous and disease-associated. Brain J Neurol. 2023;146(6):2557–69. https://doi.org/10.1093/brain/awad059.